Industry news & insights

LATTICE MEDICAL announces the success of the first breast reconstruction operation with the MATTISSE implant
LATTICE MEDICAL announces the success of the first breast reconstruction operation with the MATTISSE implant

|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.

Learn more
Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke
Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke

Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.

Learn more
Launch of Vik Atopic Dermatitis in Arabic
Launch of Vik Atopic Dermatitis in Arabic

After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.

Learn more

Latest Insights